Aurobindo Pharma Ltd : Q4FY17 Results.
Amir Shaikh / 30 May 2017
Total sales for this quarter, Q4FY17, came in at Rs. 3641.63 cr. This represents a 6.77 per cent sequential decline and 0.88 per cent YoY decline.
Aurobindo Pharma Ltd. reported its results for the quarter ended March 31, 2017, after market hours on 29th May.
Total sales for this quarter, Q4FY17, came in at Rs. 3641.63 cr. This represents a 6.77 per cent sequential decline and 0.88 per cent YoY decline.
Operating profit (EBIT) for the recently concluded quarter amounted to Rs. 721.24 cr and the EBIT margin stood at 19.81 per cent.
In terms of the bottom-line, the company reported a PAT figure of Rs. 532.45 crore which represents a sequential QoQ decline of 7.97 per cent and a YoY decline of 4.02 per cent.
The company's stock which opened for trading at Rs. 506 on the BSE and surged by 8.42 per cent after the results were declared and it is currently trading close to Rs. 561.35 mark.
Aurobindo Pharma is an India-based company. The Company is engaged in manufacturing of generic pharmaceuticals and active pharmaceutical product. The company's product portfolio includes CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.